Start Date
August 31, 2022
Primary Completion Date
January 31, 2024
Study Completion Date
June 30, 2024
Ceftolozane-tazobactam IV
Empiric Ceftolozane-tazobactam IV 3g over 1 hour every 8 hours. The dose will be reduced to 1.5g 8 hourly in patients with CrCl of 30-50 ml/min, and to 750mg every 8 hours in those with CrCl of 15-29 ml/min. Patients on hemodialysis will receive 2.25g loading dose followed by 450mg every 8 hours.
Hamad Medical Corporation, National Center for Cancer Care and Research, Doha
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Hamad Medical Corporation
INDUSTRY